Partners for
building investing in developing commercializing
life-changing healthcare
technologies
Co-Chair and Partner
Dr. Moll’s innovation career began during medical training when he invented the safety trocar, which helped create the field of modern laparoscopic surgery. He subsequently co-founded Endotherapeutics to commercialize the device, which was acquired by U.S. Surgical. Dr. Moll holds a B.A. degree in economics from the University of California at Berkeley, a M.S. degree in management from Stanford University, and a M.D. from the University of Washington. He is a distinguished speaker and lecturer, a prolific inventor and is the author of numerous scientific articles. He currently serves on the boards of several healthcare companies, including Procept BioRobotics, Inc. (Chairman – NASDAQ: PRCT), ShockWave Medical (NASDAQ: SWAV), Avail Medsystems, and RefleXion Medical.
Co-Chair and Partner
With over thirty years of experience founding and funding healthcare companies, Jay Watkins is a veteran of the medtech industry. Mr. Watkins career in healthcare began when he co-founded Origin Medsystems in the late 1980’s, a venture funded medical technology start-up that was subsequently acquired by Eli Lilly & Company. After Lilly formed Guidant, he joined the Management Committee and served as president of several divisions, including the Minimally Invasive Surgery Group, and Heart Rhythm Technologies. While at Guidant, Mr. Watkins initiated the development of a minimally invasive vein harvesting technology which has been used to treat more than three million patients worldwide; he also co-founded Gynecare, a women’s health care company which was spun out, taken public, and subsequently acquired by Johnson & Johnson. In addition, he was the founding President of Compass, Guidant’s corporate business development and new ventures group where he led venture investments in fourteen companies including Impella (acquired by Abiomed; NASDAQ: ABMD) and Intuitive Surgical (NASDAQ: ISRG). Most recently Mr. Watkins was a general partner at De Novo Ventures where he represented the firm’s investments in several healthcare companies including Lumend (sold to Johnson and Johnson), Precision Light (sold to Allergan), Loma Vista (sold to CR Bard). He is an active individual investor and currently serves as Chairman of Reflexion Medical and Avail Medsystems. He served as Chairman of Recor Medical before its sale to Otsuka Holdings in 2017. He also served as Chairman of Shockwave prior to its public offering in 2019 and continues to serve as a member of the Board (NASDAQ: SWAV).
Prior to founding Origin, Mr. Watkins held management positions in several start-ups, including Microgenics Corporation (acquired by Boehringer Mannheim), and was a consultant with McKinsey & Company. Mr. Watkins teaches at the Stanford Byers Center for Biodesign and is a Lecturer in Management at the Graduate School of Business, Stanford University. Mr. Watkins received his MBA from Harvard Business School and his undergraduate degree from Stanford University.
Partner
Colby Wood has over 25 years of investment experience in both public and private companies with expertise in healthcare and medical devices. He has been actively involved as an investor, asset gatherer and business development executive for early-stage companies in both the financial services and medical technology sectors. Prior to founding Sonder Capital in 2018, Mr. Wood was a Portfolio Manager and Equity Research Analyst with Oechsle International Advisors in London and Boston where he was responsible for medical technology investments globally. Previously Mr. Wood worked as consultant at Freeman & Company, a boutique investment bank offering mergers and acquisitions and related advisory services, capital raising, underwriting and strategic management consulting to financial institutions. He currently serves on the boards of Procept BioRobotics, Inc. (NASDAQ: PRCT) and is Chairman of Potrero Medical.
Mr. Wood holds a B.A. from University of Delaware and an MBA in Finance and Entrepreneurship from the F.W. Olin Graduate School of Business at Babson College.
Managing Partner
Ms. Garrett has received multiple honorary fellowships including being one of the first recipients of the Ferolyn Fellowship. Ms. Garrett holds a B.S. in Mechanical Engineering from Franklin W. Olin College of Engineering and is a graduate of the Stanford University Biodesign fellowship.
Partner
Mr. McGibbon holds a B.S. in Materials Engineering from the University of Cincinnati, an M.S. in Management, Technology, and Economics from the Swiss Federal Institute of Technology in Zurich (ETH Zurich) and is a graduate of the Stanford University Biodesign Fellowship.
Consulting CFO
Besides providing CFO services to Sonder, Tom is the CFO and former VC Practice Leader for Kranz Consulting. He was previously the CFO – Administrative Partner at Tenaya Capital, CFO – Principal at Sanderling Ventures, and held senior management positions at Nicholas-Applegate Capital Management, State Street Bank, and Putnam Investments where he specialized in mutual fund custody, accounting & administration, and operations. Tom is a CPA (inactive) and earned his credentials while employed by KPMG and PricewaterhouseCoopers. He received his B.S., Cum Laude, from Boston College.
Senior Operations Associate
Ms. Meehan holds a B.S. in Economics from the Wharton School at the University of Pennsylvania and is a CFA Charterholder.
Senior Associate
She is a graduate of two fellowships in medtech entrepreneurship and leadership—the Stanford Biodesign Fellowship and the Ferolyn Fellowship Leadership Initiative at the Fogarty Institute of Innovation. She graduated from Stanford University with a Bachelor’s degree in Biomechanical Engineering and a Master’s degree in Mechanical Engineering.
Venture Partner
Dr. Brinton received his bachelor’s degree from the University of California, San Diego in biomedical engineering, and his medical degree from the Chicago Medical School. He completed his internship, residency, and fellowships in both cardiology and interventional cardiology at Stanford.
SONDER ADVANTAGE
Sonder Capital invests in teams and technologies that can transform healthcare in the medical device, diagnostic and healthtech sectors. We are Foundational Investors – we commit our energy and capital early to guide and support companies from inception to acquisition or IPO. We look for big ideas that will change lives.
Core to our success is our ability and willingness to be actively engaged with the companies we invest in, partnering with our entrepreneurs as strategic advisors and providing more than just capital. We believe in getting involved at the early stages of a company which allows us to help entrepreneurs navigate those critical early decisions that can have lasting impact on long-term success.
Our insight into what it takes to bring innovative technologies to market stems from decades of operating experience in the medtech industry. As founders, executives, and board members, we’ve overcome many of the hurdles faced by entrepreneurs.
What is a Sonder Deal?
We partner with entrepreneurs who have a passion for making an impact on patients’ lives and are inventing transformational technologies and business models. We look for these key attributes in every investment:
Investment Portfolio
uLink
uLink Labs is developing an ultrasound technology platform for powering future implantables smaller than a grain of rice.
Spirair
Pioneering minimally invasive solutions for ENTs
Brius
BRIUS is revolutionizing the field of orthodontics with a truly invisible solution for straightening teeth that takes less than half the time of traditional braces.
Neptune Medical
Ziteo
Ziteo is fundamentally reinventing medical imaging to detect, localize, and treat tumors early.
Vitestro
Vitestro is transforming patient care by developing an autonomous blood drawing technology.
Our Team
We have spent our careers dedicated to the medtech community and making a difference in patient lives. We started Sonder Capital with a shared passion for bringing a new source of capital to this industry and helping build great medtech companies.
Commitment to Diversity
We recognize there is a gap today in the diversity of the voices heard by the venture community and the number of female and minority run businesses that receive venture backed funding. We want to be part of changing this.
While we traditionally only take inbound pitches from our established referral network, if you as a CEO or Founder are a minority, a woman or another underrepresented individual in the industry, we accept direct requests without a referral. Please email us your pitch deck or one page overview to closethegap@sondercapital.com and we commit to setting up an introductory call or replying with direct feedback on why the opportunity is not a fit with our thesis.
Our diversity metrics (January 2023 – December 2023):
%
of pitches seen presented by female CEOs or Founders
%